Skip to content

Twice vs Thrice Weekly Hemodialysis: Clinical Outcomes and Quality of Life

Clinical Outcomes and Health-Related Quality of Life in Patients Receiving Twice- Versus Thrice-Weekly Maintenance Hemodialysis: A Prospective Comparative Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07821788
Enrollment
130
Registered
2026-09-16
Start date
2026-09-10
Completion date
2028-02-10
Last updated
2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Failure, Chronic, Quality of Life

Keywords

Twice-weekly hemodialysis, Thrice-weekly hemodialysis, KDQOL-36, Residual kidney function, Quality of life

Brief summary

This prospective cohort study aims to compare clinical outcomes and health-related quality of life between adults receiving established twice-weekly versus thrice-weekly maintenance hemodialysis at Assiut University Hospitals.

Detailed description

Thrice-weekly maintenance hemodialysis is the conventional schedule. Twice-weekly hemodialysis is used selectively in patients with residual kidney function. Local prospective comparative data in Egypt are limited. This observational study will include adults with end-stage kidney disease receiving established twice-weekly or thrice-weekly in-center maintenance hemodialysis. Patients will be followed according to their prescribed schedule without research-driven changes. Health-related quality of life will be assessed using the Arabic KDQOL-36 at baseline, 3 months, and 6 months. Clinical outcomes including adequacy, residual kidney function, hospitalization, and mortality will be recorded.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \- Age 18 years or older * Established end-stage kidney disease requiring maintenance hemodialysis * Receiving in-center maintenance hemodialysis at Assiut University Hospitals * On maintenance hemodialysis for at least one month before enrollment * Established twice-weekly or thrice-weekly schedule prescribed by the treating team * Clinically stable at recruitment * Able to understand and respond to the questionnaire * Written informed consent

Exclusion criteria

* \- Acute kidney injury without established end-stage kidney disease * Hemodialysis for less than one month * Peritoneal dialysis or kidney transplantation during follow-up * Acute severe illness requiring intensive care at recruitment * Severe cognitive, psychiatric or neurological impairment preventing reliable questionnaire responses * Active malignancy with expected survival too short to complete follow-up * Temporary dialysis solely for an acute indication * Refusal to participate * Permanent transfer to another dialysis center during follow-up

Design outcomes

Primary

MeasureTime frameDescription
Health-related quality of life scoreAt baseline, 3 months, and 6 monthsMean total score of the Arabic Kidney Disease Quality of Life-36 (KDQOL-36) questionnaire. The KDQOL-36 score ranges from 0 to 100; higher scores indicate better health-related quality of life.

Secondary

MeasureTime frameDescription
Dialysis adequacyUp to 6 monthsMean single-pool Kt/V (for thrice-weekly) or weekly Kt/V incorporating residual kidney clearance (for twice-weekly).
Residual urine outputUp to 6 monthsMean daily urine volume (mL/day) in patients with residual kidney function.
Hospitalization rateUp to 6 monthsProportion of patients requiring hospital admission during follow-up.
Interdialytic weight gainUp to 6 monthsMean interdialytic weight gain (kg).
MortalityUp to 6 monthsProportion of patients who die during the follow-up period.

Contacts

CONTACTJustin g shawky, Resident
Justen.18313387@med.aun.edu.eg01281006606
STUDY_CHAIRmarwa k abdo, prof

Internal Medicine Department, Assiut University Hospitals

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 18, 2026